Marktkapitalisierung: $3.774T 1.890%
Volumen (24h): $117.0644B 9.650%
  • Marktkapitalisierung: $3.774T 1.890%
  • Volumen (24h): $117.0644B 9.650%
  • Angst- und Gier-Index:
  • Marktkapitalisierung: $3.774T 1.890%
Kryptos
Themen
Cryptospedia
Nachricht
Cryptostopics
Videos
Top -Nachrichten
Kryptos
Themen
Cryptospedia
Nachricht
Cryptostopics
Videos
bitcoin
bitcoin

$114720.362772 USD

-0.06%

ethereum
ethereum

$3679.931631 USD

3.08%

xrp
xrp

$3.057833 USD

1.50%

tether
tether

$0.999889 USD

-0.02%

bnb
bnb

$766.427054 USD

1.33%

solana
solana

$169.325846 USD

3.04%

usd-coin
usd-coin

$0.999801 USD

0.01%

tron
tron

$0.334792 USD

2.22%

dogecoin
dogecoin

$0.208867 USD

3.09%

cardano
cardano

$0.753413 USD

1.95%

hyperliquid
hyperliquid

$38.743306 USD

0.17%

stellar
stellar

$0.410709 USD

-0.43%

sui
sui

$3.557841 USD

1.67%

chainlink
chainlink

$16.944222 USD

1.95%

bitcoin-cash
bitcoin-cash

$571.484092 USD

3.65%

Nachrichtenartikel zu Kryptowährungen

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

May 13, 2025 at 11:14 pm

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

iotaMotion, Inc., a pioneer in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is currently being applied as part of a pre-market clinical investigation at University Hospital of Zurich, headed by Professor Alexander Huber. This study marks a significant step in expanding access to iotaMotion's innovative technology, which is designed to optimize the precision and safety of cochlear implant surgery.

The iotaSOFT® Insertion System, already commercialized in the United States, offers a unique robotic-assisted approach to inserting electrode arrays used in cochlear implants. The system is designed to provide extremely slow and consistent insertion, which is particularly important for preserving delicate intracochlear structures and enabling optimal positioning of the electrode array. Moreover, the system's advanced capabilities allow for real-time monitoring of ECochG signals, enabling surgeons to make dynamic adjustments to insertion parameters to achieve optimal electrode placement.

"We are thrilled to see the first use of the iotaSOFT® Insertion System outside of the United States at such a prestigious institution as University Hospital of Zurich," stated Mike Lobinsky, President & CEO of iotaMotion. "The team at Zurich has been an exceptional partner, and we look forward to continuing our relationship as we work together to advance cochlear implant care and explore techniques that have never been used in a clinical setting prior to this study."

iotaMotion is committed to expanding the availability of its robotic-assisted systems to surgeons and patients worldwide. The company's mission is to empower surgeons with the tools they need to perform surgery with unmatched precision and control, ultimately leading to better outcomes for patients.

"This collaboration with iotaMotion aligns perfectly with our commitment to pushing the boundaries of hearing health technology and improving the lives of patients with hearing loss," added Professor Huber. "We are honored to be the first center in Europe to introduce this groundbreaking system and contribute to its global launch."

iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, focused on developing and commercializing robotic-assisted systems for cochlear implant surgery. The company's mission is to revolutionize cochlear implant surgery by harnessing robotic technology to enhance the precision, safety, and effectiveness of surgical procedures.iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures and optimize the insertion for optimal IV stimulation. The system is commercially available in the United States and currently undergoing a pre-market clinical investigation in other global markets. For more information, visit www.iotamotion.com or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@iotamotion.com.

Originalquelle:yahoo

Haftungsausschluss:info@kdj.com

Die bereitgestellten Informationen stellen keine Handelsberatung dar. kdj.com übernimmt keine Verantwortung für Investitionen, die auf der Grundlage der in diesem Artikel bereitgestellten Informationen getätigt werden. Kryptowährungen sind sehr volatil und es wird dringend empfohlen, nach gründlicher Recherche mit Vorsicht zu investieren!

Wenn Sie glauben, dass der auf dieser Website verwendete Inhalt Ihr Urheberrecht verletzt, kontaktieren Sie uns bitte umgehend (info@kdj.com) und wir werden ihn umgehend löschen.

Weitere Artikel veröffentlicht am Aug 05, 2025